Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
RESEARCH TOOLSreports
Holding LXRX?
Track your performance easily
Earnings Data
Report Date
Mar 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.13Last Year’s EPS
-$0.2Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -40.00%
|Next Earnings Date:Mar 12, 2025
Earnings Call Sentiment|Neutral
The call highlighted significant progress in clinical development and strategic partnerships, particularly the resubmission of the NDA for ZYNQUISTA and the Viatris agreement. However, challenges were noted with modest sales growth for INPEFA and increased financial losses. The FDA Advisory Committee's negative vote on ZYNQUISTA's benefits versus risks is a notable setback.Company Guidance
During the Lexicon Pharmaceuticals' Q3 2024 earnings call, the company provided guidance on several key metrics. They reported net sales of $1.7 million for INPEFA, reflecting 8% quarter-on-quarter growth and $4.5 million year-to-date. The company ended the quarter with $258.4 million in cash and investments, excluding a $25 million upfront payment from a licensing agreement with Viatris. R&D expenses increased to $25.8 million, primarily due to late-stage development programs, while SG&A expenses rose to $39.6 million, reflecting higher marketing costs and severance expenses. The net loss for the quarter was $64.8 million, or $0.18 per share, compared to a net loss of $50.5 million, or $0.21 per share, in the same period last year. Additionally, the company is progressing with its Phase III study for sotagliflozin in hypertrophic cardiomyopathy and expects top-line data from the Phase IIb study of LX9211 in Q1 2025.NDA Resubmission for ZYNQUISTA
Completed resubmission of the NDA for ZYNQUISTA for glycemic control in people with type 1 diabetes and chronic kidney disease. The FDA Advisory Committee Meeting was held on October 31, and the company is working towards the PDUFA goal date of December 20, 2024.
Progress in Clinical Development
Phase III study for sotagliflozin in hypertrophic cardiomyopathy (HCM) is underway, and the Phase IIb study for LX9211 in diabetic peripheral neuropathic pain (DPNP) has completed enrollment screening earlier than anticipated.
Viatris Licensing Agreement
Exclusive licensing agreement completed for sotagliflozin outside the U.S. and Europe with Viatris, including a $25 million upfront payment and potential for $200 million in milestone payments.
Financial Position
Ended the quarter with $258.4 million in cash and investments, excluding the $25 million payment received from Viatris in the fourth quarter.
---
LXRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LXRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $1.19 | $1.09 | -8.40% |
| Aug 01, 2024 | $2.02 | $1.70 | -15.84% |
| May 02, 2024 | $1.70 | $1.74 | +2.35% |
| Mar 11, 2024 | $2.17 | $2.81 | +29.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Lexicon Pharmaceuticals (LXRX) report earnings?
Lexicon Pharmaceuticals (LXRX) is schdueled to report earning on Mar 12, 2025, TBA Not Confirmed.
What is Lexicon Pharmaceuticals (LXRX) earnings time?
Lexicon Pharmaceuticals (LXRX) earnings time is at Mar 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LXRX EPS forecast?
LXRX EPS forecast for the fiscal quarter 2024 (Q4) is -$0.13.
---